Evidence map›Paper›PMID 34729939›Full record

ArticleInternational journal of laboratory hematology2022

IER3 (IEX-1) dysregulation serves as a potential prognostic factor in acute myeloid leukemia patients.

Shandong Ke, Xin Zhang, Xiuzhi Xiang, Yalan Lu, Hongyu An

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of laboratory hematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Shandong KeDepartment of Hematology, Huangshi Central Hospital of EDong Medial Group, Affiliated Hospital of Hubei Polytechnic University, Huangshi, China.
Xin ZhangDepartment of Hematology, Huangshi Central Hospital of EDong Medial Group, Affiliated Hospital of Hubei Polytechnic University, Huangshi, China.ORCID https://orcid.org/0000-0002-9876-7829
Xiuzhi XiangEmergency Department, Huangshi Central Hospital of EDong Medial Group, Affiliated Hospital of Hubei Polytechnic University, Huangshi, China.
Yalan LuDepartment of Hematology, Huangshi Central Hospital of EDong Medial Group, Affiliated Hospital of Hubei Polytechnic University, Huangshi, China.
Hongyu AnDepartment of Hematology, Huangshi Central Hospital of EDong Medial Group, Affiliated Hospital of Hubei Polytechnic University, Huangshi, China.
Hubei Polytechnic University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionImmediate early response 3 (IER3) has association with hematological malignancies' risk and prognosis, such as myelodysplastic syndrome, while its relation to acute myeloid leukemia (AML) is not clear. This study aimed to explore the correlation of IER3 with AML risk, clinical characteristics, complete remission (CR), event-free survival (EFS), and overall survival (OS).

methodsA total of 93 de novo AML patients were included in this study. In addition, 30 patients with non-hyperplasia hematologic malignancies requiring bone marrow testing (as disease controls) and 30 health donors (as health controls) were also recruited. Bone morrow samples of AML patients (before treatment), disease controls (before treatment), and health controls (at donation) were collected. IER3 in bone marrow mononuclear cells was detected by reverse transcription-quantitative polymerase chain reaction.

resultsIER3 was increased in AML patients compared with disease controls and health donors (both P < .001), and receiver operating characteristic (ROC) curve showed that IER3 had certain capability of distinguishing AML patients from disease controls (area under curve (AUC): 0.735, 95% confidence interval (CI): 0.650-0.820), and health donors (AUC: 0.789, 95% CI: 0.712-0.866). Meanwhile, IER3 was correlated with FLT3-ITD mutation (P = .030) and poor NCCN risk stratification (P = .031) in AML patients. Moreover, IER3 had negative association with CR in AML patients (P = .022), and showed certain potential in discriminating CR patients from non-CR patients (AUC: 0.655, 95% CI: 0.533-0.777). Besides, IER3 was negatively associated with EFS (P = .033), but not OS (P = .083) in AML patients.

conclusionIER3 dysregulation serves as a potential prognostic factor in AML patients.

Indexed as

Leukemia, Myeloid, AcuteMyelodysplastic SyndromesApoptosis Regulatory Proteinsfms-Like Tyrosine Kinase 3Gene Expression Regulation, LeukemicHumansMembrane ProteinsMutationPrognosisRemission InductionApoptosis Regulatory Proteinsfms-Like Tyrosine Kinase 3IER3 protein, humanMembrane Proteinsacute myeloid leukemiaclinical characteristicsdisease riskimmediate early response 3prognosis

Identifiers

PMID34729939
PMCPMC9298238
OpenAlexW3208042404

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.